Key result
Baseline SGLT2 inhibitor use linked to ~77% lower odds of follow-up ascites after hospitalization.
Why the study?
Sodium-glucose cotransporter-2 inhibitors (SGLT2i) may benefit fluid retention in cirrhosis, but evidence in decompensated patients remained limited.
Does baseline SGLT2 inhibitor use reduce the presence of documented ascites at follow-up in patients with cirrhosis and type 2 diabetes mellitus after a first hospitalization for ascites?
Cohort (n=103)
Yes
Does baseline SGLT2 inhibitor use reduce the presence of documented ascites at follow-up in patients with cirrhosis and type 2 diabetes mellitus after a first hospitalization for ascites?
In patients with cirrhosis and T2DM hospitalized for a first episode of ascites, baseline SGLT2i use was associated with significantly lower odds of documented ascites during follow-up without worsening renal function or survival.
Answers are grounded in this paper and cite their sources.
Should not yet change practice in cirrhosis; hypothesis-generating for SGLT2 inhibitor benefit on ascites and requires randomized confirmation.
INTRODUCTION: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) may benefit fluid retention in cirrhosis, but evidence in decompensated patients remains limited. We evaluated the association between SGLT2i and documented ascites during follow-up in patients with cirrhosis and type 2 diabetes mellitus (T2DM) after a first episode of ascites. METHODS: A two-center retrospective cohort study of patients with cirrhosis and T2DM hospitalized for a first episode of ascites between 2017 and 2025 in Spain. Patients were classified according to SGLT2i use before admission. The primary endpoint was the presence of documented ascites at scheduled follow-up assessments after discharge. Secondary outcomes included relevant clinical and biochemical outcomes. RESULTS: Among 103 patients, 27 (26.2%) received SGLT2i and 76 (73.8%) did not. Median follow-up was 52 weeks [26-104]. SGLT2i users had a lower proportion of documented ascites (13/26 vs 53/66; 50% vs 80.3%; p=0.004). This association persisted after adjustment for potential confounders (aOR 0.23, 95% CI 0.08-0.66; p=0.006), with consistent results in a 6-month sensitivity analysis. No significant differences were observed in hospitalizations for ascites, for overall liver decompensation, LVPs, RA, hepatic encephalopathy, acute kidney injury or survival. Serum creatinine and sodium did not show differences between groups. 5/27 (18.5%) patients discontinued treatment. CONCLUSIONS: SGLT2i use was associated with a lower proportion of documented ascites after a first episode. Prospective studies are needed to establish their efficacy and safety in decompensated cirrhosis.
No takes yet. Share an insight, caveat, or question.
Mínguez et al. (2026) conducted a cohort in Cirrhosis and type 2 diabetes mellitus hospitalized for a first episode of ascites (n=103). SGLT2 inhibitors vs. No SGLT2 inhibitor use before admission was evaluated on Presence of documented ascites at scheduled follow-up assessments after discharge (aOR 0.23, 95% CI 0.08-0.66, p=0.006). Baseline SGLT2 inhibitor use was associated with lower documented ascites at follow-up after a first ascites hospitalization.
Synapse has enriched 10 related papers. Consider them for comparative context: